Syros Pharmaceuticals, Inc.
SYRS · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | -$164,574 | -$94,654 | -$86,558 | -$84,038 |
| Dep. & Amort. | $2,252 | $2,967 | $3,018 | $3,035 |
| Deferred Tax | $0 | $0 | -$16,458 | $326 |
| Stock-Based Comp. | $10,434 | $11,410 | $10,354 | $10,939 |
| Change in WC | $5,055 | -$5,517 | -$10,602 | $10,052 |
| Other Non-Cash | $37,126 | -$37,271 | $706 | $2,322 |
| Operating Cash Flow | -$109,707 | -$123,065 | -$99,540 | -$57,364 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -$272 | -$1,241 | -$1,245 | -$3,336 |
| Net Acquisitions | $0 | $0 | $0 | $0 |
| Inv. Purchases | -$50,968 | $0 | -$51,408 | $0 |
| Inv. Sales/Matur. | $87,017 | $68,426 | $0 | $50,000 |
| Other Inv. Act. | $1,560 | $0 | $0 | $0 |
| Investing Cash Flow | $37,337 | $67,185 | -$52,653 | $46,664 |
| Financing Activities | – | – | – | – |
| Debt Repay. | -$65 | -$291 | -$265 | $39,378 |
| Stock Issued | $43,270 | $119,761 | $70,337 | $102,273 |
| Stock Repurch. | $0 | -$81 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 |
| Other Fin. Act. | $257 | $11,656 | $439 | $1,302 |
| Financing Cash Flow | $43,462 | $131,045 | $70,511 | $142,953 |
| Forex Effect | $0 | $0 | $0 | $0 |
| Net Chg. in Cash | -$28,908 | $75,165 | -$81,682 | $132,253 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $170,553 | $95,388 | $177,070 | $44,817 |
| End Cash | $141,645 | $170,553 | $95,388 | $177,070 |
| Free Cash Flow | -$109,979 | -$124,306 | -$100,785 | -$60,700 |